CN105777612A - Medicine composition for treating children recurrent respiratory infection - Google Patents
Medicine composition for treating children recurrent respiratory infection Download PDFInfo
- Publication number
- CN105777612A CN105777612A CN201610125453.6A CN201610125453A CN105777612A CN 105777612 A CN105777612 A CN 105777612A CN 201610125453 A CN201610125453 A CN 201610125453A CN 105777612 A CN105777612 A CN 105777612A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutical composition
- respiratory tract
- tract infection
- infantile respiratory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medicine composition for treating the children recurrent respiratory infection.The medicine composition contains an effective amount of compound and a pharmaceutically-acceptable carrier.The compound is of a structure as shown in the description.The compound has a remarkable effect on pathogenic bacteria causing the children recurrent respiratory infection and can be developed into a new clinically-effective medicine composition.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition treating infantile respiratory tract infection repeatedly.
Background technology
Recurrent respiratory tract infection (RRI) is usual diseases of childhood, and sickness rate is about 20%, has a strong impact on children ' s healthy growth.Children patient hypoimmunity gains public acceptance as main pathogenic, also has bibliographical information and serum zinc, selenium and other trace elements concentration reduction relevant.In the patient illness part secretions of infantile respiratory tract infection repeatedly, find that Corallium Japonicum Kishinouye streptomycete ATCC23901 is also one of pathogenic bacterium therein in the recent period.
Summary of the invention
It is an object of the invention to provide a kind of pharmaceutical composition treating infantile respiratory tract infection repeatedly.
In order to realize the purpose of the present invention, the present invention provides a kind of compound treating infantile respiratory tract infection repeatedly, and this compound has having structure:
The present invention also provides for a kind of pharmaceutical composition treating infantile respiratory tract infection repeatedly, and described pharmaceutical composition comprises the compound of effective dose and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizer or corrigent.
Preferably, described diluent is sugar derivatives, starch derivatives or cellulose derivative.
Preferably, described diluent is lactose.
Preferably, described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
The present invention also provides for compound purposes in the medicine of preparation treatment infantile respiratory tract infection repeatedly, and this compound has having structure:
Preferably, described infection is caused by Corallium Japonicum Kishinouye streptomycete ATCC23901.
The present invention also provides for compound purposes in the medicine of preparation vitro inhibition Corallium Japonicum Kishinouye streptomycete ATCC23901, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to the material of biologic activity or the character not eliminating compound as herein described, such as carrier or diluent.This kind of material is applied to individuality and is not resulted in undesirable biological action or not with harmful way and any component interaction in the compositions comprising it.
" pharmaceutically acceptable carrier " includes any and all of solvent as the term is employed herein, disperse medium, coating material, surfactant, antioxidant, preservative (such as antibacterial, antifungal), isotonic agent, absorption delay agent, salt, preservative, drug stabilizing agent, binding agent, excipient, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with the inconsistent carrier of active component, consider to use any conventional carrier in treatment or pharmaceutical composition.
The compound of the present invention is notable for the pathogen effect causing infantile respiratory tract infection repeatedly, it is possible to develop into pharmaceutical composition effectively new clinically.
Detailed description of the invention
Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art's basic thought according to the present invention, various modifications may be made or improves, but without departing from the basic thought of the present invention, all within the scope of the present invention.
The research of experimental example the compounds of this invention purposes in the medicine of preparation vitro inhibition Corallium Japonicum Kishinouye streptomycete ATCC23901
Bacteriostatic test
Use following compounds, adopt filter paper enzyme classical in this area to carry out bacteriostatic test, wherein:
The structural formula of target compound is:
For examination strain Corallium Japonicum Kishinouye streptomycete ATCC23901 purchased from Fu Xiang bio tech ltd, Shanghai.
Culture fluid
Nutrient agar and nutrient broth, purchased from Chen Yu experimental facilities company limited of BeiJing ZhongKe.
Test method
Corallium Japonicum Kishinouye streptomycete ATCC23901 is inoculated in agar plate nutritional solution plane, uniformly gathers during inoculation.
Weighing target compound 0.01 gram, add 28000 ml sterile waters, ultrasonic 30 minutes, then the filtering with microporous membrane of 0.22 μm, obtained solution.The aseptic circular filter paper sheet of tweezer, sprays above-mentioned solution to complete wetting, is attached in the agar plate nutritional solution plane of inoculated bacteria.Agar plate is placed in the incubator of 37 DEG C, incubation 4 hours.Measure the diameter of antibacterial ring.Measure and average for 3 times.
1.4 results
The average diameter of the antibacterial ring of Corallium Japonicum Kishinouye streptomycete ATCC23901 is 13.68mm, and this shows that target compound has the effect of extremely strong vitro inhibition Corallium Japonicum Kishinouye streptomycete ATCC23901.
Claims (9)
1. the compound treating infantile respiratory tract infection repeatedly, it is characterised in that this compound has having structure:
2. the pharmaceutical composition treating infantile respiratory tract infection repeatedly, it is characterised in that described pharmaceutical composition comprises the compound of effective dose and pharmaceutically acceptable carrier, and described compound has having structure:
3. the pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly according to claim 2, it is characterised in that described pharmaceutically acceptable carrier is diluent, disintegrating agent, binding agent, lubricant, stabilizer or corrigent.
4. the pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly according to claim 3, it is characterised in that described diluent is sugar derivatives, starch derivatives or cellulose derivative.
5. the pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly according to claim 4, it is characterised in that described diluent is lactose.
6. the pharmaceutical composition for the treatment of infantile respiratory tract infection repeatedly according to claim 3, it is characterised in that described pharmaceutical composition is powder, microgranule, granule, capsule or tablet.
7. compound purposes in the medicine of preparation treatment infantile respiratory tract infection repeatedly, it is characterised in that this compound has having structure:
8. purposes according to claim 7, it is characterised in that described infection is caused by Corallium Japonicum Kishinouye streptomycete ATCC23901.
9. compound purposes in the medicine of preparation vitro inhibition Corallium Japonicum Kishinouye streptomycete ATCC23901, it is characterised in that this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610125453.6A CN105777612A (en) | 2016-03-07 | 2016-03-07 | Medicine composition for treating children recurrent respiratory infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610125453.6A CN105777612A (en) | 2016-03-07 | 2016-03-07 | Medicine composition for treating children recurrent respiratory infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105777612A true CN105777612A (en) | 2016-07-20 |
Family
ID=56388084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610125453.6A Pending CN105777612A (en) | 2016-03-07 | 2016-03-07 | Medicine composition for treating children recurrent respiratory infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105777612A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1742786A (en) * | 2005-09-29 | 2006-03-08 | 辽宁中医学院 | Chinese medicine for preventing and controlling infants repeated respiratory tract inflammation and producing method |
| CN1850151A (en) * | 2006-03-06 | 2006-10-25 | 董瑞 | Chinese medicinal liquid of acupuncture point cupping for preventing and treating infant's respiration diseases, and preparing method |
| CN1872306A (en) * | 2005-06-03 | 2006-12-06 | 邱静宇 | Preparation of Chinese traditional medicine for treating baby's cough, and preparation method |
| CN101407554A (en) * | 2008-10-30 | 2009-04-15 | 高莉萍 | Sodium carboxymethylstarch and preparation thereof |
| CN105232540A (en) * | 2015-09-29 | 2016-01-13 | 王洪燕 | Drug combination for treating infection after burn |
-
2016
- 2016-03-07 CN CN201610125453.6A patent/CN105777612A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1872306A (en) * | 2005-06-03 | 2006-12-06 | 邱静宇 | Preparation of Chinese traditional medicine for treating baby's cough, and preparation method |
| CN1742786A (en) * | 2005-09-29 | 2006-03-08 | 辽宁中医学院 | Chinese medicine for preventing and controlling infants repeated respiratory tract inflammation and producing method |
| CN1850151A (en) * | 2006-03-06 | 2006-10-25 | 董瑞 | Chinese medicinal liquid of acupuncture point cupping for preventing and treating infant's respiration diseases, and preparing method |
| CN101407554A (en) * | 2008-10-30 | 2009-04-15 | 高莉萍 | Sodium carboxymethylstarch and preparation thereof |
| CN105232540A (en) * | 2015-09-29 | 2016-01-13 | 王洪燕 | Drug combination for treating infection after burn |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083364B (en) | A kind of pharmaceutical composition for the treatment of the infantile respiratory tract infection that enterobacter cloacae causes | |
| CN105198903B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN105395538B (en) | A kind of pharmaceutical composition treating acute upper respiratory tract infection | |
| CN105777612A (en) | Medicine composition for treating children recurrent respiratory infection | |
| CN105412076B (en) | Compound purposes in the medicine of preparation treatment infantile diarrhea | |
| CN105085503A (en) | Medicine composition for treating respiratory tract infection | |
| CN105622619A (en) | Medicine composition for treating periodontitis | |
| CN105348183A (en) | Pharmaceutical composition for treating gynecology-and-obstetrics postoperative low-fever symptom | |
| CN105232540A (en) | Drug combination for treating infection after burn | |
| CN105232542B (en) | A kind of pharmaceutical composition for the treatment of infantile pneumonia | |
| CN105294535A (en) | Pharmaceutical composition used for treating pelvic inflammation | |
| CN105237542A (en) | Medicine composition for treating gynecological diseases | |
| CN105061331A (en) | Pharmaceutical composition for eliminating phlegm for children | |
| CN105232550B (en) | A kind of pharmaceutical composition treating chronic pelvic inflammatory disease | |
| CN105687189A (en) | Medicine composition for treating upper respiratory tract infection | |
| CN105287478B (en) | A kind of pharmaceutical composition treating gastritis | |
| CN105232504A (en) | Medicine composition for treating infant recurrent respiratory tract infections | |
| CN105732522A (en) | Medicine composition for treating periodontitis | |
| CN105218460A (en) | A kind of pharmaceutical composition for the treatment of enteritis | |
| CN105796564A (en) | Medicine composition for preventing and treating infection of teeth and dental pulp | |
| CN105125546A (en) | Medicine composition for treating postoperative wound infection | |
| CN105748477B (en) | A kind of medicine treating infantile enteritiss | |
| CN105748478B (en) | A kind of medicine treating infantile diarrhea | |
| CN105769899B (en) | A kind of medicine treating infantile pneumonia | |
| CN105348270A (en) | Medicine composition preventing dental body and dental pulp infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160720 |
|
| WD01 | Invention patent application deemed withdrawn after publication |